Polypharmacy in heart failure patients

Vittoria Mastromarino, Matteo Casenghi, Marco Testa, Erica Gabriele, Roberta Coluccia, Speranza Rubattu, Massimo Volpe

Research output: Contribution to journalArticlepeer-review


In heart failure (HF), the progressive use of multiple drugs and a complex therapeutic regimen is common and is recommended by international guidelines.With HF being a common disease in the elderly, patients often have numerous comorbidities that require additional specific treatment, thus producing a heavy pill burden. Polypharmacy, defined as the chronic use of five or more medications, is an underestimated problem in the management of HF patients. However, polypharmacy has an important impact on HF treatment, as it often leads to inappropriate drug prescription, poor adherence to pharmacological therapies, drug-drug interactions, and adverse effects. The growing complexity of HF patients, whose mean age increases progressively and who present multiple comorbidities, suggests the need for newer models of primary care to improve the management of HF patients. Self-care, telemonitoring, and natriuretic peptide-guided therapy represent promising new HF care models to face the complexity of the disease and its therapeutic regimen.

Original languageEnglish
Pages (from-to)212-219
Number of pages8
JournalCurrent Heart Failure Reports
Issue number2
Publication statusPublished - 2014


  • Adherence
  • Brain natriuretic peptide
  • Comorbidities
  • Heart failure
  • Polypharmacy
  • Self-care

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)
  • Emergency Medicine
  • Medicine(all)


Dive into the research topics of 'Polypharmacy in heart failure patients'. Together they form a unique fingerprint.

Cite this